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Abstract 
Introduction: Complete hydatidiform moles (CHMs) can develop into gestational trophoblastic 
neoplasia (GTN). Because CHMs are allografts to the patients in terms of an androgenetic origin, 
some immunological reactions may be involved in the development of GTN from CHMs. 
However, no study has analyzed the relationship between ABO types of moles and GTN 
occurrence, especially from the viewpoint of immune compatibility. This study aimed to evaluate 
the effect of ABO blood group on the prognosis of androgenetic CHMs. 
Material and methods: A total of 129 patients who were diagnosed as having CHMs based on 
multiplex short tandem repeat polymorphism analysis between January 2007 and February 2016 
were included. The ABO blood types of the patients were determined serologically and those of 
molar tissues were determined by single nucleotide polymorphisms in the ABO gene using a 
high-resolution melting assay with real-time polymerase chain reaction. The incidence of GTN 
was compared based on patients’ ABO blood types and the ABO compatibility between patients 
and their molar tissues. 
Results: The overall incidence of GTN was 17.1% (22/129). GTN occurred in 10.8% (4/37), 
14.8% (8/54), 22.2% (6/27), and 36.4% (4/11) of type O, A, B, and AB patients, respectively (P 
= 0.202, Fisher’s exact test). Type AB patients tended to develop GTN compared with other 
blood type patients (P = 0.093, Fisher’s exact test). In ABO type of CHMs, GTN occurrence was 
not significantly different as 16.4% (10/64), 16.0% (8/50), and 22.2% (4/18) of type O, A, and B 
CHMs, respectively (P = 0.854, Fisher’s exact test). The ABO types of patients and molar tissues 
were immunologically compatible in 94 cases and incompatible in 35 cases. GTN occurred in 18 
(19.1%) of the compatible cases and 4 (11.4%) of the incompatible cases; the occurrence was not 
significantly different (P = 0.223). 
Conclusions: Patients with type AB tended to develop GTN compared with those with types A, B, 
and O. However, ABO compatibility between patients and molar tissues had no relationship with 
GTN occurrence. Another GTN developing mechanism would exist rather than immunological 
rejection based on ABO type of androgenetic CHMs. 
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Introduction 
Hydatidiform mole (HM) is an abnormal pregnancy characterized by swollen chorionic villi and 
proliferative trophoblast cells. It has the potential risk for developing gestational trophoblastic 
neoplasia (GTN). The two categories of HMs according to their cytogenetic origin are complete 
HMs (CHMs) as androgenetic diploid and partial HMs (PHMs) as diandric monogynic triploid.1 
The incidences of GTN from CHMs and PHMs are 15-20% and 1-2%, respectively.1, 2 Thus, 
androgenetic CHMs are major source of GTN, but the developing mechanism of GTN has not 
been revealed. Characteristically, both CHMs and GTN from CHMs are complete allografts for 
patients because they are derived from conceptus tissues without maternal chromosomes.1, 2 
Development of GTN from CHMs may be attributable to histocompatibility between patients 
and their molar tissues.  
The ABO blood type is a major human alloantigen system that is composed of A and B antigens 
expressed on red blood cells, and anti-A and anti-B antibodies against those antigens in serum. In 
addition to their expression on red blood cells, ABO antigens are expressed in other human cells 
and tissues.3 Recently, numerous studies about the relationship between ABO blood types and 
various diseases have been reported.4-8 A few studies indicated the effect of ABO blood types 
against the outcomes of pregnancy such as preeclampsia,9 but the effects were discordance 
among the studies. 
The association between ABO blood types and gestational trophoblastic diseases has been 
investigated for the last several decades. In the 1970s, the combination of patient’s and her 
husband’s ABO blood types was applied on the risk factor to predict the sensitivity of single 
agent chemotherapy for GTN.10-12 Even in Japan, a regional cohort study of 4,547 HM patients 
showed that a patient with blood type AB is associated with GTN occurrence.13 These reports 
suggested that immunological reaction by ABO antigen and antibody may play a role in 
eliminating neoplastic trophoblasts on the process of developing GTN from HMs. The patients 
with blood type AB might not reject HMs because they do not have anti-A nor anti-B antibody. 
However, no study has analyzed the relationship between ABO blood types and GTN from the 
viewpoint of immune compatibility because of the difficulty of determination of ABO types of 
HMs. 
In this study, we aimed to evaluate the effect of ABO blood types on the risk of GTN from 
CHMs in a retrospective observational cohort setting. We focused on androgenetic CHMs only 
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but not on PHMs genetically diagnosed using consecutive cases to assess the genuine effect of 
ABO blood types on the incidence of GTN. We hypothesized that ABO immune compatibility 
correlated with GTN occurrence. To evaluate them, we determined the ABO types of CHM using 
single nucleotide polymorphism (SNP) genotyping. The incidence of GTN was then compared 
based on ABO compatibility between patients and their molar tissues. 
 
Material and methods 
Patient recruitment and clinical management 
Patients were referred to our hospital because of suspected molar pregnancy between January 
2007 and February 2016. After transvaginal ultrasonographic examination and preoperative 
evaluation including blood tests of human chorionic gonadotropin (hCG) and blood types, 
evacuation of uterine content was performed in Chiba University Hospital. Intrauterine tissues 
were submitted to the pathological department for routine histopathological evaluation. After the 
evacuations, the patients were followed up by monitoring serum hCG levels weekly, biweekly, 
and monthly before they reach to 50 mIU/mL, 10 mIU/mL, and cutoff level, respectively. GTN 
was diagnosed using the FIGO 2000 criteria.14 In cases of GTN, we further evaluated the patient 
using imaging studies such as transvaginal sonography, chest X-ray, and chest and abdominal 
computed tomography. We classified them as low- or high-risk according to the FIGO 2000 risk 
score.14 
Molecular genetic diagnosis 
For patients who consented to join the molecular genetic diagnostic study, we performed short 
tandem repeat (STR) polymorphism analysis using the patient’s blood and the villous tissues as 
reported previously.15-17 Briefly, DNA extraction of the blood and tissues was performed using 
QIAamp DNA Mini Kit and QIAamp Blood DNA Mini Kit (QIAGEN, Tokyo, Japan), 
respectively, according to the manufacturer’s instructions. STR analysis was conducted using a 
PowerPlex 16HS Kit (Promega, Madison, WI, USA), as previously described.17 Diagnostic 
algorithm was previously reported in detail. If one or more villous loci did not show any 
maternal alleles, the case was classified as an androgenetic CHM; otherwise, it was classified as 
a biparental conceptus. In a biparental conceptus, based on the existence of three allelic loci or 
the lack thereof, the concepti were classified as diandric monogynic PHM or biparental abortion, 
respectively.  
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Subject selection and clinical data collection 
Patients with androgenetic CHM classified by STR analysis were enrolled into this study (Figure 
1). PHM cases and biparental abortion cases were excluded. Hysterectomy cases were included. 
Patients with complete hydatidiform moles coexisting with a live fetus were also included. 
Clinical and laboratory data including patient’s age, pre-evacuated serum hCG, and ABO blood 
type were collected from medical records. 
Determination of ABO histo-blood type of patients 
ABO histo-blood type of the patients was determined using standard erythrocyte antiserum 
agglutination methods at the clinical laboratory department of Chiba University Hospital. 
Determination of ABO genotype of patients and molar tissues 
ABO genotype was determined using DNA samples extracted from patients’ blood and molar 
tissues for molecular diagnosis. The A and B antigens are converted from H antigen by the 
glycosyltransferase activity encoded by the ABO gene.3 The ABO gene with type A allele 
encodes N-acetylgalactosaminyltransferase, which converts H antigen into A antigen, whereas 
that with type B allele encodes galactosyltransferase, which converts H antigen into B antigen. 
Type O allele makes the frame shift and encodes incomplete peptide chain without 
glycosyltransferase activity.3 The ABO gene is located on chromosome 9, which genotype is 
known to be defined by SNPs (Figure 2A).3 
To determine the ABO genotype, we used real-time polymerase chain reaction (PCR) and 
high-resolution melting (HRM) assay, which detect the difference in melting pattern of each 
amplicon. We targeted two SNP loci: rs8176719 in exon 6 and rs8176749 in exon 7 (Figure 2A). 
Primers were designed to amplify 67-bp products for rs8176719 (forward 
5′-TCCATGTGCAGTAGGAAGGA-3′ and reverse 5′-GTGCCCTCCCAGACAATG-3′) and 
70-bp products for rs8176749 (forward 5′-ACGAGAGCCACCTGAACAAG-3′ and reverse 
5′-CACAAGTACTCGGGGGAGAG-3′). Real-time PCR was performed using the LightCycler® 
Nano Instrument (Roche Diagnostics, Tokyo, Japan). The PCR mixtures consisted of genomic 
DNA (3 ng), 1 × LightCycler® 480 High Resolution Melting Master (Roche Diagnostics, Tokyo, 
Japan), 2.5 mM MgCl2, and 200 nM of each forward and reverse primer in a total 10 μl volume. 
The thermocycling conditions used for both primer pairs were as follows: 95 °C for 10 min; 45 
cycles of denaturation at 95 °C for 10 s, annealing at 60 °C for 25 s, extension at 72 °C for 15 s, 
then hold at 95 °C for 60 seconds and 40 °C for 60 seconds, and finished by HRM procedure 
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from 60 °C to 99 °C at 0.050 °C/s. The absence of artifacts and nonspecific PCR products was 
confirmed by agarose gel electrophoresis. HRM analysis were performed using LightCycler 
NanoSoftware 1.1 (Roche Diagnostics, Tokyo, Japan). Genotyping experiments with HRM 
analysis was repeated independently twice. 
The representative results of HRM genotyping were confirmed by the Sanger method using 
BigDye Terminator Kit, version 1.1 (Applied Biosystems, Foster City, CA) and ABI prism 310 
Genetic Analyzer (Applied Biosystems, Foster City, CA).  
Algorithm of the estimation of blood types from the HRM data  
HRM analyses of rs8176719 and rs8176749 loci make the SNP patterns as G/G, G/del, del/del 
and G/G, G/A, A/A, respectively (Figure 2B). The algorithm of estimated genotypes and blood 
types is shown in Table 1.  
Determination of ABO compatibility 
Incompatible cases were defined as the cases that patients had the antibody against the antigen 
encoded by the ABO gene of molar tissues. According to that definition, type A patients are 
incompatible with type BB, BO and AB CHMs. Type B patients are incompatible with type AA, 
AO and AB CHMs. Type O patients are incompatible with all types except for type OO of CHMs, 
and type AB patients were compatible with all genotypes of CHMs. 
Statistical analysis 
Data are presented as median (interquartile range), means ± standard deviation, or number and 
percentage. Statistical analysis was performed using JMP® Pro 13 (SAS Institute Inc., Cary, NC, 
USA). Fisher's exact test was used for categorical variables. Statistical analysis for multiple 
groups was performed using one-way ANOVA, Kruskal-Wallis test, and Fisher’s exact test 
depending on the valuable type. Cochran-Armitage trend test was used to investigate the GTN 
incidence for the antibody score, which we defined as the number of anti-A and/or anti-B 
retention antibodies; we assigned the antibody score as 2, 1, 1, and 0 for blood types O, A, B, and 
AB, respectively. The association between ABO compatibility and GTN occurrence was 
analyzed using Fisher’s exact test. 
Ethical approval 
The study protocols were approved by Institutional Review Board (Biomedical Research Ethics 
Committee of the Graduate School of Medicine, Chiba University, No. 674 and No. 882) and the 
research was performed after obtaining written, informed consent from each participant. 
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Results 
Enrolled subjects and demographic characteristics 
In total, 206 patients were referred to Chiba University Hospital for suspected molar pregnancy 
and underwent evacuation, except one patient who was treated with primary hysterectomy. We 
compared the patient’s blood and their villous tissue with multiplex STR analysis. One hundred 
and thirty-three patients were diagnosed with androgenetic CHM by STR analysis. Among them, 
four patients were excluded from this study because the DNA samples extracted from the molar 
tissues were insufficient to determine ABO blood type. Finally, 129 patients were enrolled into 
this retrospective observational cohort study (Figure 1). 
Of the patients, 37 (28.7%), 54 (41.8%), 27 (20.9%), and 11 (8.5%) were serologically classified 
as types O, A, B, and AB, respectively (Table 2). The ABO blood type distribution of the subjects 
was approximately equal to the general Japanese population.18 The patient’s age, gravidity, parity, 
gestational weeks at termination of pregnancy, and pre-evacuated serum hCG levels were not 
different among each group (Table 2). One hundred and eleven (86.0%) patients were classified 
to have homozygous CHMs, whereas the other patients were classified to have heterozygous 
CHMs. The distribution did not differ by the patients’ blood types. 
Relationship between patients’ ABO blood types and GTN incidence 
The GTN incidence was 17.1% in total. All GTN patients were classified as low-risk GTN using 
FIGO 2000 risk score.14 The incidences were varied from 10.8% (type O) to 36.4% (type AB) (P 
= 0.202, Fisher’s exact test for 2 × 4 matrix) (Table 3). Type AB patients tended to develop GTN 
compared with the other blood type patients (P = 0.093, Fisher’s exact test for 2 × 2 matrix). This 
result suggested that patients who have neither anti-A nor anti-B antibodies had higher potential 
to develop GTN. Thus, we further analyzed the trend test by assigning the antibody score as 
described in the Material and methods section. The GTN incidence was significantly higher in 
patients with lower antibody score (P = 0.036, Cochran-Armitage trend test) (Table 3).  
Validation of ABO blood type determination of HRM assay 
We performed HRM analysis for the two SNP loci (rs8176719 and rs8176749) (Figure 2A). 
Representative HRM curves are shown in Figure 2B. Three genotypes as G/G, del/del, G/del on 
rs8176719, and G/G, A/A, A/G on rs8176749 could be separated clearly. According to the 
determination algorithm of blood type (Table 1), all patients’ blood types were determined using 
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the HRM assay. Compared with the patients’ histo-blood type to the determined blood types, all 
cases were in agreement (Table 4). Thus, HRM assay could be used to determine ABO types of 
the molar tissues. 
ABO blood type of molar tissues 
The ABO genotype of molar tissues was classified as OO, AA, AO, BB, BO, and AB in 61, 45, 5, 
17, 1 and 0 patients, respectively (Table 5). Most CHMs were homozygous; thus, heterozygous 
genotypes, such as AO, BO, and AB, were rare. This distribution was compatible with the one 
estimated using the Japanese allele frequency (Table 5).18 The GTN incidence was not 
significantly different by ABO types of molar tissues (P = 0.854, Fisher’s exact test) (Table 5). 
Relationship between ABO compatibility and GTN incidence 
Compatibility of ABO blood type was determined according to the combination of the patient’s 
and molar tissue’s ABO blood type as shown in Table 6. The ABO blood types of patients and 
molar tissues were compatible in 94 cases and incompatible in 35 cases. GTN occurred in 18 
(19.1%) of the compatible cases and 4 (11.4%) of the incompatible cases, but the occurrence was 
not significantly different (P = 0.223) (Table 7). 
 
Discussion 
In this study, we revealed that type AB patients were associated with GTN occurrence, whereas it 
could not be explained by ABO immune compatibility. Using the serological method of blood 
type determination, direct comparison of immune compatibility between the patients and the 
mole was impossible because the mole’s ABO type could not be determined. To the best of our 
knowledge, we introduced a genotyping method to determine ABO types of CHM. We 
hypothesized that the ABO immune compatibility between the patients and their moles should 
determine the development of GTN. 
In 1971, Bagshawe et al. described the relationship between the ABO blood type and 
trophoblastic neoplasia, which is now called GTN.10, 11 The relationship between the mating 
patterns of ABO blood type and the prognosis of GTN was evaluated. Based on the data, the 
combination of ABO blood type of patients and their husbands had been adopted in the WHO 
risk score.12 Later, ABO blood type was discounted in the new version of the risk score of GTN 
(FIGO 2000 risk score)14, 19 because their significance had not been confirmed.20, 21 The older 
version of WHO risk score used the ABO blood types to classify low- or high-risk GTN. Our 
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study discussed about the risk of GTN development from CHMs because the hypothesis that 
immunological rejection might affect in eliminating trophoblasts after evacuation of HM would 
be attractive. 
Patients with AB blood type tended to have a higher risk of GTN, but it was not statistically 
significant. The result was consistent with the previous cohort study in Aichi prefecture in Japan; 
the study included both types of HM (CHM and PHM).13 Patients with blood type AB do not 
have anti-A antibody nor anti-B antibody. Thus, they might not reject the ABO-incompatible 
allografts in addition to the compatible allografts. In this background, we raised the ABO 
immune compatible hypothesis for developing GTN. However, the compatibility of ABO types 
between the patients and their molar tissues did not correlate with the GTN occurrence. Thus, 
there seemed to be another relationship between patients’ ABO blood types and GTN occurrence. 
From the viewpoint of the immunological hypothesis, the individual difference of ABO antibody 
titers may affect the development of GTN. Anti-A and anti-B antibodies include IgG, IgM, and 
IgA, and their titers are influenced mainly by environmental factors.22 Lower antibody titers may 
make it difficult to eliminate circulating trophoblasts after CHM evacuation, resulting in GTN 
occurrence. Another hypothesis was that the expression level of ABO antigens on the trophoblast 
surface differed among each CHM and affected the immunological rejection. ABO antigens have 
been reported not to express in the placenta, but no data are available about the expression of 
ABO antigen on the circulating trophoblast surface. This point of view requires future 
evaluation.  
Except for the immunological hypothesis, another possible explanation for the relationship 
between ABO blood type and GTN occurrence is that the activity of coagulation activity or cell 
adhesion molecules may be related to ABO blood type. Recently, the relationship between ABO 
blood type and the disease or the various pathological conditions, such as thrombotic vascular 
diseases,7 coronary artery disease,5 cancer development,4 and mortality of severe trauma,8 has 
been reported. AB blood type could be related to coagulation tendency as thrombotic features.7 If 
the clots with molar trophoblast cells were the starting materials of metastasis, the higher risk of 
AB blood type might be acceptable. Moreover, genetic variation in ABO gene has been reported 
to correlate with circulating levels of proinflammatory cytokines and cell adhesion molecules, 
such as tumor necrosis factor alpha,23 soluble intracellular adhesion molecule 1,24 soluble 
E-selectin, and P-selectin.25 These factors play an important role in carcinogenesis and tumor 
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metastasis. 
Evaluation of GTN incidence is not easy because the basal population of CHM and PHM among 
molar pregnancies might be different among studies. The discrimination between CHM and 
PHM could be difficult in particular cases.16 The incidences of GTN are quite different according 
to the types of molar pregnancy ― 15-20% from CHMs and 1-2% from PHMs.1, 2 In this study, 
we used consecutive androgenetic CHM cases, which were most reliable in diagnostic accuracy.1, 
15 The uniform selection of patients in this study was an advantage. The limitation of this study 
was the small sample size; thus, the tendency discussed above was not conclusive. GTN is a rare 
tumor. A nationwide study is warranted to resolve the question.  
 
Conclusion 
Type AB patients tended to develop GTN. However, ABO compatibility between patients and 
their molar tissues did not show significant relationship with GTN occurrence. Higher GTN 
incidence in AB blood type patients could not be explained by the immunological rejection 
mechanism based on ABO type of androgenetic CHMs. 
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Figure 1 
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Figure 2 
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Figure legends 
 
Figure 1 Flow diagram for selection of study subjects.  
CHM, complete hydatidiform mole; HM, hydatidiform mole; PHM, partial hydatidiform mole; 
STR, short tandem repeat 
 
Figure 2 ABO genes, single nucleotide polymorphisms, and discrimination using the 
high-resolution melting assay. 
A: Schematic presentation of exon 6 and exon 7 of ABO gene. A, B, and O alleles have grouped 
single nucleotide polymorphisms, which could determine the genotypes using the combination of 
the two loci. B: High-resolution melting (HRM) assay for rs8176719 discriminated the three 
genotypes as G/G, del/del, and G/del. C: HRM assay for rs8176749 discriminated the three 
genotypes as G/G, A/A, and G/A.  
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Table 1 
Algorithm of the estimation of blood types from the SNP genotyping data 
 
rs8176719 rs8176749 
Determined 
genotype 
Histo-blood type SNP Possible 
genotype 
SNP Possible 
genotype 
G/G AA AB BB G/G AA AO OO AA A 
G/G AA AB BB G/A AB BO AB AB 
G/G AA AB BB A/A BB BB B 
G/del AO BO G/G AA AO OO AO A 
G/del AO BO G/A AB BO BO B 
G/del AO BO A/A BB *  
del/del OO G/G AA AO OO OO O 
del/del OO G/A AB BO *  
del/del OO A/A BB *  
 
*These combinations between the two loci should not be assigned theoretically. 
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Table 2 
Baseline characteristics in each blood group of the patients 
 
 Total 
N = 129 
Type O 
N = 37 
Type A 
N = 54 
Type B 
N = 27 
Type AB 
N = 11 
P value 
Frequency (%)  28.7 41.8 20.9 8.5  
Reported Japanese frequency a 
(%) 
 29.4 38.3 22.3 10.0  
Characteristics       
Age, years (±SD) 32.2 (±7.7) 31.3 (±8.0) 31.4 (±7.9) 33.2 (±6.3) 36.0 (±7.6) 0.23b 
Gravidity, median (IQR) 2 (1–7) 2 (1–5) 2.5 (1–7) 3 (1–6) 2 (1–6) 0.08c 
Parity, median (IQR) 1 (0–5) 0 (0–3) 1 (0–5) 1 (0–4) 0 (0–3) 0.12c 
TOP, weeks, median (IQR) 9.6 
(7–24) 
9.9 
(7–24) 
9.9 
(7–17) 
9.1 
(7–19) 
10.3 
(8–16) 
0.25c 
Pre-evacuated hCG, 
mIU/mL median (IQR) 
155805 
(14332–
1892762) 
148321 
(14332–
1120000) 
166261 
(19857–
1680784) 
142491 
(33479–
1155847) 
183793 
(69360–
1892762) 
0.39c 
Cytogenetic classification       
Homozygous CHM (%) 111 (86.0) 31 (83.8) 49 (90.7) 21 (77.8) 10 (83.8) 
0.41d 
Heterozygous CHM (%) 18 (14.0) 6 (16.2) 5 (9.3) 6 (22.2) 1 (16.2) 
a Maeda K, Nakamura S, Murakami C, et al. ABO genotyping by TaqMan assay and allele frequencies in a 
Japanese population. Leg Med (Tokyo). 2013;15(2):57-60. 
b One-way ANOVA 
c Kruskal-Wallis test 
d Fisher’s exact test 
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Table 3 
Patients’ ABO blood types and GTN occurrence 
 
 Total Type O Type A Type B Type AB P value 
n 129 37 54 27 11  
GTN (%) 22 
(17.1%) 
4 
(10.8%) 
8 
(14.8%) 
6 
(22.2%) 
4 
(36.4%) 
0.202a 
 
18 
(15.3%)  
4 
(36.4%) 
0.093a 
       
Antibody score*  2 1 1 0  
Anti-A antibody  ＋ － ＋ －  
Anti-B antibody  ＋ ＋ － －  
Incidence of GTN  10.8% 17.3% (14/81) 36.4% 0.036b 
* Antibody score is defined as the number of A and B antibodies. 
a Fisher’s exact test 
b Cochran-Armitage trend test 
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Table 4 
Validation of the determined ABO blood type by genotyping of HRM assay compared with the patient’s 
histo-blood type 
 
Patient’s 
genotype 
Determined ABO 
blood type 
Patient’s histo-blood type 
O A B AB 
OO Type O 37 0 0 0 
AA 
Type A 
0 14 0 0 
AO 0 40 0 0 
BB 
Type B 
0 0 3 0 
BO 0 0 24 0 
AB Type AB 0 0 0 11 
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Table 5 
Distribution of molar ABO genotypes and GTN occurrence 
 
Mole genotype n (%) 
Estimated frequency 
(%)a 
GTN (%)b 
Histo-blood 
type 
OO 61 47.2 52.9 10 (16.4) 10 (16.4) O 
AA 45 34.8 27.1 8 (17.8) 
8 (16.0) A 
AO 5 3.9 1.5 0 
BB 17 13.2 16.9 3 (17.7) 
4 (22.2) B 
BO 1 0.8 1.0 1 
AB 0 0 0.5 0 0 AB 
aEstimated frequency was calculated based on the reported Japanese ABO allele frequency (A : B : O = 28.1 : 
17.7 : 54.2)*, assuming that homozygous CHMs accounted 90% of all CHMs. 
bIncidence of GTN was not significantly different according to ABO histo-blood type of moles (P = 0.854, 
Fisher’s exact test). 
*Maeda K, Nakamura S, Murakami C, et al. ABO genotyping by TaqMan assay and allele frequencies in a 
Japanese population. Leg Med (Tokyo). 2013;15(2):57-60. 
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Table 6 
Combination of patient’s and mole’s ABO blood type 
 
Mole 
genotype 
Patients’ blood typea 
Total (n) 
O A B AB 
OO 14 28 14 5 61 
AA 16 19 6 4 45 
AO 2 2 1 0 5 
BB 5 5 5 2 17 
BO 0 0 1 0 1 
AB 0 0 0 0 0 
aBold numbers indicate the ABO incompatible combination between the anti A/B antibody of patients and the 
ABO antigen on the moles. 
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Table 7 
Relationship between ABO incompatibility and development of gestational trophoblastic neoplasia 
 
 Total GTN (%)  
Compatible 94 18 (19.1%) 
P = 0.223a 
Incompatible 35 4 (11.4%) 
aFisher’s exact test 
 
